These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. DNA-based immunisation against rabies and rabies-related viruses: towards multivalent vaccines. Perrin P; Jacob Y; Desmézières E; Tordo N Dev Biol (Basel); 2000; 104():151-7. PubMed ID: 11713814 [TBL] [Abstract][Full Text] [Related]
3. From plasmids to protection: a review of DNA vaccines against infectious diseases. Laddy DJ; Weiner DB Int Rev Immunol; 2006; 25(3-4):99-123. PubMed ID: 16818367 [TBL] [Abstract][Full Text] [Related]
4. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses. Borrego B; Fernandez-Pacheco P; Ganges L; Domenech N; Fernandez-Borges N; Sobrino F; Rodríguez F Vaccine; 2006 May; 24(18):3889-99. PubMed ID: 16563575 [TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Klinman DM; Klaschik S; Sato T; Tross D Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313 [TBL] [Abstract][Full Text] [Related]
6. Overview of recent DNA vaccine development for fish. Kurath G Dev Biol (Basel); 2005; 121():201-13. PubMed ID: 15962483 [TBL] [Abstract][Full Text] [Related]
7. Use of attenuated bacteria as delivery vectors for DNA vaccines. Daudel D; Weidinger G; Spreng S Expert Rev Vaccines; 2007 Feb; 6(1):97-110. PubMed ID: 17280482 [TBL] [Abstract][Full Text] [Related]
9. Use of B7 costimulatory molecules as adjuvants in a prime-boost vaccination against Visna/Maedi ovine lentivirus. de Andrés X; Reina R; Ciriza J; Crespo H; Glaria I; Ramírez H; Grilló MJ; Pérez MM; Andrésdóttir V; Rosati S; Suzan-Monti M; Luján L; Blacklaws BA; Harkiss GD; de Andrés D; Amorena B Vaccine; 2009 Jul; 27(34):4591-600. PubMed ID: 19538997 [TBL] [Abstract][Full Text] [Related]
10. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction. Mills KH Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777 [TBL] [Abstract][Full Text] [Related]
15. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Bracci L; La Sorsa V; Belardelli F; Proietti E Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607 [TBL] [Abstract][Full Text] [Related]
16. Modulating specific priming of immune effector functions by DNA-based vaccination strategies. Reimann J; Schirmbeck R Dev Biol (Basel); 2000; 104():15-24. PubMed ID: 11713813 [TBL] [Abstract][Full Text] [Related]
18. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine. Wingard JB; Anderson B; Weissman D Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164 [TBL] [Abstract][Full Text] [Related]
19. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Dietrich G; Spreng S; Favre D; Viret JF; Guzman CA Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465 [TBL] [Abstract][Full Text] [Related]
20. Human clinical trials of plasmid DNA vaccines. Liu MA; Ulmer JB Adv Genet; 2005; 55():25-40. PubMed ID: 16291211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]